Search results for "double-blind method"

showing 10 items of 631 documents

Antihyperalgesic and analgesic properties of the N-methyl-d-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic …

2006

Abstract NMDA-receptors are a major target in the prevention and treatment of hyperalgesic pain states in neuropathic pain. However, previous studies revealed equivocal results depending on study design and efficacy parameters. We tested the analgesic (generalized reduction of generation and processing of nociceptive signalling) and anti-hyperalgesic (prevention of central sensitization) properties of the NMDA-receptor antagonist neramexane and the potassium channel opener flupirtine in the intradermal capsaicin injection model. Furthermore, we tested the effect on pain summation (wind up). Eighteen healthy subjects received either a single dose of neramexane (40 mg p.o.), flupirtine (100 m…

Injections IntradermalAnalgesicAminopyridinesPainCyclopentanesPharmacologyPlaceboReceptors N-Methyl-D-AspartateDouble-Blind MethodPhysical StimulationHumansMedicineAnalgesicsCross-Over StudiesDose-Response Relationship Drugbusiness.industryNeramexaneTreatment OutcomeAnesthesiology and Pain MedicineAllodyniaNociceptionHyperalgesiaAnesthesiaNeuropathic painHyperalgesiaCapsaicinNervous System Diseasesmedicine.symptomFlupirtinebusinessmedicine.drugEuropean Journal of Pain
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct

Intercurrent factors associated with the development of open-angle glaucoma in The European Glaucoma Prevention Study

2007

Purpose: To evaluate the intercurrent factors for the development of open-angle glaucoma (OAG) in ocular hypertensive patients who were enrolled in the European Glaucoma Prevention Study (EGPS). Design: Randomized, double masked, controlled clinical trial. Methods: setting: Multicenter. study population: A total of 1,077 patients fulfilled a series of inclusion criteria, including intraocular pressure (IOP) 22 to 29 mm Hg, normal and reliable visual fields (VFs) and normal optic disks. intervention: Treatment with dorzolamide or placebo. main outcome measures: Glaucoma-related VF or optic disk changes. Clinical data were collected every six months during a five-year follow-up. Proportional …

Intraocular pressuremedicine.medical_specialtyTime Factorsgenetic structuresOpen angle glaucomaSettore MED/06 - Oncologia MedicaOptic DiskOptic diskOcular hypertensionGlaucomaThiopheneslaw.inventionCorneaDouble-Blind MethodDorzolamideRandomized controlled trialRisk FactorslawOphthalmologyConfidence IntervalsPrevalencemedicineHumansDiureticsglaucoma ocular hypertension intercurrent risk factorsAntihypertensive AgentsIntraocular PressureProportional Hazards ModelsRetrospective StudiesSulfonamidesbusiness.industryHazard ratioRetinal Hemorrhagemedicine.diseaseeye diseasesEuropeOphthalmologyTreatment OutcomeCardiovascular Diseasessense organsbusinessGlaucoma Open-AngleFollow-Up Studiesmedicine.drug
researchProduct

Clinical efficacy of a bleaching enzyme-based toothpaste. A double-blind controlled clinical trial.

2015

Abstract Objectives To assess the efficacy of a bleaching enzyme-based toothpaste. Material and methods A randomized clinical trial was carried out, comprising 48 participants with teeth exhibiting color A3 or higher according to the Vita Classical guide. One-half of the sample received the bleaching enzyme-based toothpaste (White Kin ® ), while the other received placebo toothpaste. Both products were supplied in identical containers and had the same composition except for the active components. The teeth color was measured with a spectrophotometer. The patients were instructed to brush their teeth three times a day during 3 min with the assigned product, during 12 weeks. The color measure…

LightnessAdultMalebusiness.product_categoryAdolescentDentistryCarbamide PeroxidePlaceboOral hygienelaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawStatistical significanceTooth BleachingMedicineHumansUrea030212 general & internal medicineLactoperoxidaseColorimetryTooth Bleaching AgentsGeneral DentistryTooth Bleaching AgentsToothpastebusiness.industry030206 dentistryMiddle AgedPeroxidesTreatment OutcomeSpectrophotometryColorimetryFemalebusinessToothpastesJournal of dentistry
researchProduct

The effect of orally administered probiotic Lactobacillus reuteri -containing tablets in peri-implant mucositis: a double-blind randomized controlled…

2015

Background and Objectives Probiotics create a biofilm and protect the oral tissues against the action of periodontal pathogenic bacteria. The aim of this study was to evaluate the effects of the oral probiotic Lactobacillus reuteri Prodentis upon the peri-implant health of edentulous patients with dental implants and peri-implant mucositis, establishing comparisons vs implants without peri-implant disease. Material and Methods A double-blind, placebo-controlled, prospective cross-over study was made. The patients were all edentulous and were divided into two groups, (A) no peri-implant disease, and (B) peri-implant mucositis affecting one or more implants. Patients with peri-implantitis wer…

Limosilactobacillus reuteriMaleMucositismedicine.medical_specialtyPeri-implant mucositisDentistryPlaceboGastroenterologylaw.inventionPlacebosProbioticDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineMucositisHumansProspective StudiesProspective cohort studyAgedCross-Over Studiesbiologybusiness.industryProbioticsMiddle Agedmedicine.diseasebiology.organism_classificationCrossover studyLactobacillus reuteriDental ImplantationTreatment OutcomeCytokinesPeriodonticsFemalebusinessTabletsJournal of Periodontal Research
researchProduct

Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia

2012

Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy of eltrombopag for increasing platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia and chronic liver disease who are undergoing an elective invasive procedure.We randomly assigned 292 patients with chronic liver disease of diverse causes and platelet counts of less than 50,000 per cubic millimeter to receive eltrombopag, at a dose of 75 mg daily, or placebo for 14 days before a planned elective invasive procedure that was performed within 5 days after the last dose. The primary end point was the avoidance of a platelet transfusion before, during, and up to 7…

Liver CirrhosisMaleCirrhosisChronic liver diseaseBenzoateslaw.inventionchemistry.chemical_compoundRandomized controlled triallawReceptorsClinical endpoint80 and overMedicineCIRRHOSISAged 80 and overBenzoic AcidsGeneral MedicineCHRONIC LIVER DISEASEMiddle AgedHydrazinesThrombopoietinElective Surgical ProceduresAnesthesiaFemaleElective Surgical ProcedureReceptors ThrombopoietinAdultAdolescentEltrombopagELTROMBOPAGHemorrhagePlatelet TransfusionPlaceboYoung AdultDouble-Blind MethodElectiveSurgical Procedures ElectiveHumansAgedTHROMBOCYTOPENIA; ELTROMBOPAG; CIRRHOSIS; CHRONIC LIVER DISEASESurgical Proceduresbusiness.industryPlatelet CountTHROMBOCYTOPENIAcirrhosisSettore MED/09 - MEDICINA INTERNAmedicine.diseaseThrombocytopeniaPlatelet transfusionchemistryChronic DiseasePyrazolesbusiness
researchProduct

Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial.

1998

beta-Blockers and sclerotherapy prevent long-term upper digestive rebleeding in cirrhosis but they seem ineffective for early rebleeding. We compared octreotide with a placebo for the prevention of early rebleeding in cirrhotic patients. After control of acute upper digestive bleeding, 262 consecutive cirrhotic patients were randomized to octreotide 100 microgram subcutaneously three times a day for 15 days (n = 131) or to the placebo (n = 131), in a double blind pragmatic trial in which beta-blockers and/or sclerotherapy were allowed together with the experimental treatment. Separate randomization and analysis were performed according to whether patients were eligible for beta-blockers and…

Liver CirrhosisMalemedicine.medical_specialtyRandomizationmedicine.medical_treatmentAdrenergic beta-AntagonistsOctreotidePlaceboOctreotideHemostaticsPlacebosDouble-Blind MethodMelenaRecurrenceSclerotherapymedicineSclerotherapyHumansHepatologybusiness.industryHematemesisLength of StayMiddle AgedSurgeryClinical trialSurvival RateTreatment OutcomeChemoprophylaxisFemaleComplicationVaricesbusinessGastrointestinal Hemorrhagemedicine.drugHepatology (Baltimore, Md.)
researchProduct

Early Steroid-Free Immunosuppression With FK506 After Liver Transplantation: Long-Term Results of a Prospectively Randomized Double-Blinded Trial

2010

Background. The aim of this prospective, randomized, double-blinded, placebo-controlled single center study was to evaluate an early steroid-free immunosuppression in liver transplant patients. Methods. From March 2000 to October 2004, 110 patients were included. All patients received tacrolimus and steroids during the first 2 weeks after orthotopic liver transplantation (OLT). Thereafter, patients in the steroid group (n=54) received steroids and the remaining 56 a placebo. After 6 months, the immunosuppression for all was steroid free. Thirty patients were hepatitis C positive. Five years after inclusion, patient survival, organ survival, steroid side effects, and recirrhosis in hepatitis…

Liver Cirrhosismedicine.medical_specialtyTime Factorsmedicine.medical_treatmentHypercholesterolemiaLiver transplantationSingle CenterPlaceboGastroenterologyTacrolimusPostoperative ComplicationsDouble-Blind MethodAdrenal Cortex HormonesRecurrenceInternal medicineDiabetes MellitusmedicineHumansSurvival rateAntibacterial agentTransplantationDose-Response Relationship Drugbusiness.industryGraft SurvivalImmunosuppressionHepatitis Cmedicine.diseaseHepatitis CTacrolimusLiver TransplantationSurgerySurvival RateTreatment OutcomebusinessImmunosuppressive AgentsTransplantation
researchProduct

Volume and effectiveness assessment of articain 4% versus mepivacaine 2% used in third molar surgery : randomized, double-blind, split-mouth controll…

2020

Made available in DSpace on 2021-06-25T11:06:11Z (GMT). No. of bitstreams: 0 Previous issue date: 2020-01-01 Background: The different indications for extraction of the lower third molars, require resources to manage pain and discomfort, such as, for example, adequate anesthetic techniques, and the type of anesthetic used can in-fluence the management of pain in tooth extractions. Few studies in the literature compare the anesthetics 4% articaine hydrochloride and 2% mepivacaine hydrochloride showing evidence that both allow for successful pain management. This study sought to compare the volume, efficacy and safety of these two anesthetic drugs, both associated with epinephrine at a ratio …

Local anaesthesiaVisual analogue scaleAnesthesia DentalMepivacainePainCarticaineArticaineArticaine Hydrochloridelaw.inventionCarticaineRandomized controlled trialDouble-Blind MethodlawThird molarmedicineHumansParesthesiaAnesthetics LocalGeneral Dentistrybusiness.industryResearch:CIENCIAS MÉDICAS [UNESCO]Clinical trialOtorhinolaryngologyAnesthesiaAnestheticMepivacaineTooth ExtractionUNESCO::CIENCIAS MÉDICASSurgeryMolar ThirdOral Surgerybusinessmedicine.drug
researchProduct

Bupivacaine 0.5% versus articaine 4% for the removal of lower third molars. A crossover randomized controlled trial.

2012

Objective: To compare the anesthetic action of 0.5% bupivacaine in relation to 4% articaine, both with 1:200,000 epinephrine, in the surgical removal of lower third molars. As a secondary objective hemodynamic changes using both anesthetics were analyzed. Study Design: Triple-blind crossover randomized clinical trial. Eighteen patients underwent bilateral removal of impacted lower third molars using 0.5% bupivacaine or 4% articaine in two different appointments. Preoperative, intraoperative and postoperative variables were recorded. Differences were assessed with McNemar tests and repeated measures ANOVA tests. Results: Both solutions exhibited similar latency times and intraoperative effic…

Local anesthesiaAdultMalemedicine.medical_specialtyAnestèsia en odontologiaAdolescentHemodynamicsCarticaineArticainelaw.inventionPostoperative painYoung AdultDolor postoperatoriClinical trialsRandomized controlled trialDouble-Blind MethodlawMedicineTeeth extractionHumansAnesthetics LocalGeneral DentistryExtracció dentalBupivacaineCross-Over Studiesbusiness.industryRepeated measures designAnestèsia localDent molar:CIENCIAS MÉDICAS [UNESCO]Crossover studyMolarBupivacaineSurgeryBlood pressureOtorhinolaryngologyAnesthesiaAnestheticUNESCO::CIENCIAS MÉDICASTooth ExtractionSurgeryFemaleMolar ThirdResearch-ArticleAnesthesia in dentistryOral Surgerybusinessmedicine.drugAssaigs clínicsMedicina oral, patologia oral y cirugia bucal
researchProduct